Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

Synaptogenix Inc SNPX has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer's disease (AD).
To date, the Company has dosed 58 of its target 100 patients.
Additionally, the independent Data Safety Monitoring Board (DSMB) confirmed that 40 advanced AD patients had been dosed with Bryostatin without any significant safety issues.
Price Action: SNOX shares are up 0.57% at $7.05 during the market session on the last check Wednesday.